by The global EYLEA drug market is primarily driven by the rising prevalence of retinal diseases. EYLEA injection, also known as aflibercept, is used for treating wet age-related macular degeneration and other retinal diseases that cause vision loss like diabetic retinopathy. EYLEA acts by inhibiting vascular endothelial growth factor (VEGF) and its associated angiogenesis. As VEGF is a major driver of abnormal blood vessel growth in the eyes, blocking its activity helps in treating many sights threatening retinal diseases.
The Global EYLEA Drug Market Size is estimated to be valued at US$ 8.79 Billion in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024-2031.
Key Takeaways
Key players: Key players operating in the global EYLEA drug market are Bayer, Regeneron Pharmaceuticals, Coherus BioSciences, Inc., and Klinge Biopharma. Bayer and Regeneron Pharmaceuticals together hold a major market share.
Key Opportunities: Increasing prevalence of diabetes worldwide will boost the adoption of EYLEA injections for treating diabetic retinopathy. Additionally, ongoing R&D for expanding EYLEA’s indication to treat other retinal diseases will open new avenues.
Global Expansion: Major players are expanding their geographical footprint in high growth regions like Asia Pacific and Latin America to tap the increasing patient pool. Partnerships with local players will aid global market penetration.
Market Drivers
The rising geriatric population globally susceptible to age-related macular generation and diabetic retinopathy is a key growth driver. As per estimates, over 30% of American adults will be aged 65+ by 2050. Additionally, growing incidence of diabetes due to sedentary lifestyle and obesity will further fuel the adoption of EYLEA injections. Favorable reimbursement for retinal disease treatment in developed nations and increasing healthcare expenditure in developing countries will encourage patients to seek prescribed therapy.
PEST Analysis
Political: Current government policies provide sufficient support for biopharmaceutical research and drug development. Potential changes in regulations and patent laws could impact the market.
Economic: Slowing global economic growth and rising healthcare costs may pose challenges for patient access and uptake of high-priced drugs. However, increasing expenditure on healthcare sustains market opportunities.
Social: Growing geriatric population and rising prevalence of lifestyle-induced diseases like diabetes drive the demand for innovative drugs for treatment of age-related eye diseases. Awareness programs help patients understand treatment options.
Technological: Manufacturers invest heavily in R&D to develop improved targeted therapies and drug delivery technologies. Biosimilars may capture a share of the market upon patent expiry of originator drugs.
The North America region accounted for the highest market share in terms of value sales owing to developed healthcare infrastructure and supportive reimbursement policies. Growing awareness about eye care and availability of advanced treatments also contribute to its large market size.
The Asia Pacific region is anticipated to grow at the fastest rate over the forecast period. Rising incident of diabetic retinopathy and age-related macular degeneration, improving access to healthcare facilities, increasing healthcare expenditure are some factors fueling high growth.
What Are The Key Data Covered In This Global EYLEA Drug Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors
FAQ’S
Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
